Increase in morphine antinociceptive activity by a P-glycoprotein inhibitor in cisplatin-induced neuropathy

Neuroscience Letters

Volumn 465, Issue 1, 2009, Pages 108-112

  Balayssac, David ^a,b,c   Cayre, Anne ^b,d   Ling, Bing ^a   Maublant, Jean ^b,d   Penault Llorca, Frédérique ^b,d   Eschalier, Alain ^a,b,c   Coudoré, François ^c   Authier, Nicolas ^a,b,c  

^a INSERM   (France)

^b UNIVERSITÉ CLERMONT AUVERGNE   (France)

^c UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^d CENTRE JEAN PERRIN   (France)

Author keywords

Cisplatin; Morphine; Neuropathy; P glycoprotein; Pain; Rats

Indexed keywords

CISPLATIN; GLYCOPROTEIN P; LANIQUIDAR; MORPHINE;

ANALGESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINOCICEPTION; ARTICLE; BRAIN; CONTROLLED STUDY; DRUG DOSE COMPARISON; DRUG POTENTIATION; MALE; MECHANICAL STIMULATION; MULTIDRUG RESISTANCE; NONHUMAN; PAIN THRESHOLD; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; RAT; SCIATIC NERVE; SPINAL CORD; SPINAL GANGLION;

EID: 70349205344     PISSN: 03043940     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neulet.2009.09.003     Document Type: Article

References (28)

1. Aquilante C.L., Letrent S.P., Pollack G.M., and Brouwer K.L. Increased brain P-glycoprotein in morphine tolerant rats. Life Sci. 66 (2000) 47-51
2. Authier N., Gillet J.P., Fialip J., Eschalier A., and Coudore F. An animal model of nociceptive peripheral neuropathy following repeated cisplatin injections. Exp. Neurol. 182 (2003) 12-20
3. Balayssac D., Cayre A., Authier N., Ling B., Maublant J., Eschalier A., Penault-Llorca F., and Coudore F. Involvement of the multidrug resistance transporters in cisplatin-induced neuropathy in rats. Comparison with the chronic constriction injury model and monoarthritic rats. Eur. J. Pharmacol. 544 (2006) 49-57
4. Bourasset F., Cisternino S., Temsamani J., and Scherrmann J.M. Evidence for an active transport of morphine-6-beta-d-glucuronide but not P-glycoprotein-mediated at the blood-brain barrier. J. Neurochem. 86 (2003) 1564-1567
5. Campa D., Gioia A., Tomei A., Poli P., and Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin. Pharmacol. Ther. 83 (2008) 559-566
6. Cayre A., Moins N., Finat-Duclos F., Maublant J., and Verrelle P. Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents. J. Nucl. Med. 40 (1999) 672-676
7. Chong M.S., and Bajwa Z.H. Diagnosis and treatment of neuropathic pain. J. Pain Symptom Manage. 25 (2003) 4-11
8. Crane P., Laliberte R., Heminway S., Thoolen M., and Orlandi C. Effect of mitochondrial viability and metabolism on technetium-99m-sestamibi myocardial retention. Eur. J. Nucl. Med. 20 (1993) 20-25
9. Dagenais C., Graff C.L., and Pollack G.M. Variable modulation of opioid brain uptake by P-glycoprotein in mice. Biochem. Pharmacol. 67 (2004) 269-276
10. De Vry J., Kuhl E., Franken-Kunkel P., and Eckel G. Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. 491 (2004) 137-148
11. Gilron I., Bailey J.M., Tu D., Holden R.R., Weaver D.F., and Houlden R.L. Morphine, gabapentin, or their combination for neuropathic pain. N. Engl. J. Med. 352 (2005) 1324-1334
12. Grubbs F. Procedures for detecting outlying observations in samples. Technometrics 11 (1969) 1-21
13. Jimenez-Andrade J.M., Herrera M.B., Ghilardi J.R., Vardanyan M., Melemedjian O.K., and Mantyh P.W. Vascularization of the dorsal root ganglia and peripheral nerve of the mouse: implications for chemical-induced peripheral sensory neuropathies. Mol. Pain 4 (2008) 10
14. Letrent S.P., Pollack G.M., Brouwer K.R., and Brouwer K.L. Effects of a potent and specific P-glycoprotein inhibitor on the blood-brain barrier distribution and antinociceptive effect of morphine in the rat. Drug Metab. Dispos. 27 (1999) 827-834
15. Liu X., Yang Z., Yang J., and Yang H. Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled rats. Neuropharmacology 53 (2007) 657-663
16. Lotsch J., Schmidt R., Vetter G., Schmidt H., Niederberger E., Geisslinger G., and Tegeder I. Increased CNS uptake and enhanced antinociception of morphine-6-glucuronide in rats after inhibition of P-glycoprotein. J. Neurochem. 83 (2002) 241-248
17. Lynch 3rd J.J., Wade C.L., Zhong C.M., Mikusa J.P., and Honore P. Attenuation of mechanical allodynia by clinically utilized drugs in a rat chemotherapy-induced neuropathic pain model. Pain 110 (2004) 56-63
18. Maublant J., de Latour M., Mestas D., Clemenson A., Charrier S., Feillel V., Le Bouedec G., Kaufmann P., Dauplat J., and Veyre A. Technetium-99m-sestamibi uptake in breast tumor and associated lymph nodes. J. Nucl. Med. 37 (1996) 922-925
19. Maublant J., Gachon P., and Moins N. Hexakis (2-methoxy isobutylisonitrile) technetium-99m and thallium-201 chloride: uptake and release in cultured myocardial cells. J. Nucl. Med. 29 (1988) 48-54
20. Piwnica-Worms D., Chiu M.L., Budding M., Kronauge J.F., Kramer R.A., and Croop J.M. Functional imaging of multidrug-resistant P-glycoprotein with an organotechnetium complex. Cancer Res. 53 (1993) 977-984
21. Quasthoff S., and Hartung H.P. Chemotherapy-induced peripheral neuropathy. J. Neurol. 249 (2002) 9-17
22. Randall L.O., and Selitto J.J. A method for measurement of analgesic activity on inflamed tissue. Arch. Int. Pharmacodyn. Ther. 111 (1957) 409-419
23. Saito T., Zhang Z.J., Tokuriki M., Shibamori Y., Yamamoto T., Noda I., Ohtsubo T., and Saito H. Doxorubicin ototoxicity is induced in mice by combination treatment with cyclosporin A. Acta Otolaryngol. 121 (2001) 787-793
24. Schinkel A.H., and Jonker J.W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv. Drug Deliv. Rev. 55 (2003) 3-29
25. Thomas H., and Coley H.M. Overcoming multidrug resistance in cancer: an update on the clinical strategy of inhibiting p-glycoprotein. Cancer Control. 10 (2003) 159-165
26. Tishler D.M., Weinberg K.I., Hinton D.R., Barbaro N., Annett G.M., and Raffel C. MDR1 gene expression in brain of patients with medically intractable epilepsy. Epilepsia 36 (1995) 1-6
27. van Zuylen L., Sparreboom A., van der Gaast A., van der Burg M.E., van Beurden V., Bol C.J., Woestenborghs R., Palmer P.A., and Verweij J. The orally administered P-glycoprotein inhibitor R101933 does not alter the plasma pharmacokinetics of docetaxel. Clin. Cancer Res. 6 (2000) 1365-1371
28. Wolka A.M., Huber J.D., and Davis T.P. Pain and the blood-brain barrier: obstacles to drug delivery. Adv. Drug Deliv. Rev. 55 (2003) 987-1006